echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Kelun Pharmaceutical's Tirofiban Hydrochloride and Sodium Chloride Injection Passed the Consistency Evaluation

    Kelun Pharmaceutical's Tirofiban Hydrochloride and Sodium Chloride Injection Passed the Consistency Evaluation

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On March 4, Kelun Pharmaceutical issued an announcement stating that the "Drug Supplementary Application Approval Notice" for the chemical drug "Tirofiban Hydrochloride Sodium Chloride Injection" recently approved and issued by the National Medical Products Administration.
    Pass the quality and efficacy consistency evaluation of generic drugs.

    Product specifications:

    100ml: tirofiban hydrochloride (calculated as C22H36N2O5S) 5mg and sodium chloride 0.

    250ml: tirofiban hydrochloride (calculated as C22H36N2O5S) 12.
    5mg and sodium chloride 2.

    This product is mainly used for adult patients with non-ST-elevation acute coronary syndrome with ECG changes and/or myocardial enzyme elevation within 12 hours of the last chest pain onset, to prevent early myocardial infarction; and to plan direct PCI ( Percutaneous coronary intervention) in patients with acute myocardial infarction to reduce the occurrence of major cardiovascular events.

    Tirofiban is a platelet glycoprotein IIb/IIIa receptor antagonist.
    It has the advantages of rapid onset, definite efficacy, and rapid recovery of platelet function after drug withdrawal.
    It has been approved by the European "Guidelines for Myocardial Revascularization (2018)" , China's "Acute ST-segment elevation myocardial infarction diagnosis and treatment guidelines (2019)", China's "Acute ST-segment elevation myocardial infarction rational use of thrombolytic therapy guidelines (2019)" and other domestic and foreign authoritative guidelines recommended for use.
    Tirofiban Hydrochloride Sodium Chloride Injection is a category B product of the National Medical Insurance in 2020, and its sales in China in 2019 are about 190 million yuan.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.